Revisiting trial design considerations to improve efficiency of HIV-1 vertical transmission prevention efficacy trials in infants

INTRODUCTION: While the global incidence of HIV-1 vertical transmission has reduced greatly, a persistent and unacceptable number of new infant infections continue to occur through breastfeeding. Long-acting antiretroviral agents, including injectable drugs and broadly neutralizing monoclonal antibodies, given as prophylaxis to infants hold great potential to eliminate HIV-1 transmission. However, given the low frequency of HIV-1 vertical transmission during breastfeeding in trial settings, efficient and innovative study designs will be necessary to evaluate the efficacy of agents administered to infants as prophylaxis.Key Design Considerations:We provide an overview of study design considerations and assess alternative specifications that may improve the efficiency of future trials to evaluate the efficacy of a novel agent administered to infants in preventing breastfeeding acquisition of HIV-1. We highlight key attributes of the study estimand (intervention, target population, outcomes and endpoints, intercurrent events, and population-level summaries) and discuss nuances in their specification with respect to improving efficiency. We explore alternatives to the classic randomized clinical trial framework, including augmented clinical trials that incorporate external data to supplement clinical trial data. We also provide an overview of Bayesian and transportability-based statistical analysis approaches for analyzing such augmented clinical trials. Modifications to the study design in the context of the estimand framework alone will not be sufficient to address challenges introduced by the low frequency of transmission events. Alternative study designs that incorporate external data are becoming increasingly acceptable and may help alleviate resource constraints. CONCLUSION: A multi-faceted approach will be required to design efficacy trials for postnatal prophylaxis. This work provides a guide for thinking through key study design decisions.

Authors

Institutions

Publication Details

Journal
Clinical Trials
Published
2026-11-01
DOI
https://doi.org/10.1177/17407745261491911
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Revisiting trial design considerations to improve efficiency of HIV-1 vertical transmission prevention efficacy trials in infants

Theodore Ruel, Elaine J. Abrams, Danni Wu, Dwight Edward Yin et al.
Clinical Trials
Statistical Methods in Clinical Trials
article

Revisiting trial design considerations to improve efficiency of HIV-1 vertical transmission prevention efficacy trials in infants

Theodore Ruel, Elaine J. Abrams, Danni Wu, Dwight Edward Yin, Mark J Giganti
article en

Abstract

INTRODUCTION: While the global incidence of HIV-1 vertical transmission has reduced greatly, a persistent and unacceptable number of new infant infections continue to occur through breastfeeding. Long-acting antiretroviral agents, including injectable drugs and broadly neutralizing monoclonal antibodies, given as prophylaxis to infants hold great potential to eliminate HIV-1 transmission. However, given the low frequency of HIV-1 vertical transmission during breastfeeding in trial settings, efficient and innovative study designs will be necessary to evaluate the efficacy of agents administered to infants as prophylaxis.Key Design Considerations:We provide an overview of study design considerations and assess alternative specifications that may improve the efficiency of future trials to evaluate the efficacy of a novel agent administered to infants in preventing breastfeeding acquisition of HIV-1. We highlight key attributes of the study estimand (intervention, target population, outcomes and endpoints, intercurrent events, and population-level summaries) and discuss nuances in their specification with respect to improving efficiency. We explore alternatives to the classic randomized clinical trial framework, including augmented clinical trials that incorporate external data to supplement clinical trial data. We also provide an overview of Bayesian and transportability-based statistical analysis approaches for analyzing such augmented clinical trials. Modifications to the study design in the context of the estimand framework alone will not be sufficient to address challenges introduced by the low frequency of transmission events. Alternative study designs that incorporate external data are becoming increasingly acceptable and may help alleviate resource constraints. CONCLUSION: A multi-faceted approach will be required to design efficacy trials for postnatal prophylaxis. This work provides a guide for thinking through key study design decisions.

Clinical Trials
Harvard University (US), University of California, San Francisco (US), National Institute of Allergy and Infectious Diseases (US), ICAP Global Health (US), Columbia University (US)
Openalex Percentile: Top 11%
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon